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ABSTRACT
Background: Renal transplant recipients are known to be susceptible to viral infections, 
with more severe clinical presentations compared to healthy persons. Hepatitis E is 
generally a self-limited disease, which is caused by hepatitis E virus. Recently, hepatitis 
E has become more important in organ transplant recipients, because of new findings 
regarding the potential for chronic infections in this patient group.
Objectives: This study aimed to evaluate the seroprevalence of anti-HEV IgG among kid-
ney transplant recipients in Urmia, in the north-western region of Iran.
Patients and Methods: 91 patients were selected randomly from amongst patients who 
had undergone kidney transplantation in Urmia, Iran. Each patient was tested for the 
presence of anti-HEV IgG antibody using an enzyme-linked immunosorbent assay 
(ELISA, Dia.Pro; Diagnostic Bioprobes, Italy).
Results: 28 subjects (30.8%) were seropositive for anti-HEV IgG. Seropositive patients 
were generally older than seronegative patients (P = 0.009). There was no correlation 
between HEV infection and the level of education (P = 0.206), the history of blood 
transfusion (P = 0.164), or history of pre-transplantation hemodialysis (P = 0.228). 
There was no significant difference in the serum alanine aminotransferase (ALT) levels 
of the anti-HEV seropositive and seronegative patients. Multinomial logistic regres-
sion analysis indicated no significant relationship between HEV infection and increase 
in ALT levels, even after controlling for treatment with azathioprine (P = 0.79, OR = 1.12; 
95% CI: 0.45–2.76).
Conclusion: The anti-HEV IgG antibody has a high prevalence in Iranian kidney trans-
plant recipients, and it is significantly higher in comparison with previous studies in 
the general population or in hemodialysis patients.
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  Implication for health policy/practice/research/medical education:
The prevalence rate of anti-HEV IgG in transplant recipients is independent of its prevalence in the general population. In the set-
ting of transplant recipients, the clinicians should not look merely for clinical evidence to consider hepatitis E. 
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1. Background
Hepatitis E is generally a self-limited disease, which is 
caused by hepatitis E virus (HEV) (1, 2), a non-enveloped 
single-stranded RNA virus (3). It is an endemic disease in 
developing countries in Central Asia, the Middle East, Af-
rica, and Latin America (4), and appears to be an emerg-Hepat Mon. 2011;11(8):646-651
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ing disease in industrialized countries (5). Iran, in the 
Middle East, is one of the endemic countries for HEV (6), 
with a few suspected outbreaks of HEV infection (7). The 
seroprevalence of anti-HEV IgG in healthy Iranian popu-
lations was demonstrated to be different across regions 
of Iran, ranging from 2.3% in the northern region to 11.5% 
in southern Iran (with a cumulative rate of 153/2900 sub-
jects; 5.2%) (8-12). Hepatitis E virus has been reported to 
have four different genotypes, of which genotype 1 is the 
most prevalent type and is widespread in endemic re-
gions, including most parts of Asia, including Iran, and 
northern Africa (13). The genotype of HEV causing HEV in-
fections in developed countries is mostly different from 
that in endemic regions.
The main route of HEV transmission is the fecal-oral 
route. However, several studies have also emphasized 
that transmission of HEV via non-fecal-oral routes ap-
pears to be possible (2). There are reports of HEV infec-
tion in individuals who received blood transfusions in 
endemic areas (14-16). HEV infection was thought to be 
an acute infection, which does not become chronic, with 
spontaneous recovery in almost all cases (1). However, 
several cases of persistent (chronic) HEV infection and its 
relatively rapid evolution to HEV-related cirrhosis have 
been reported in organ transplant recipients (17-19). Pre-
vious seroprevalence studies found that 6% to 15.6% of re-
nal transplant recipients were positive for anti-HEV IgG 
antibodies (5, 20, 21).
2. Objectives
Considering the differences in natural history of HEV 
infection in organ transplant recipients compared to 
other patient groups, and also different prevalence rates 
among developing and industrialized countries, this 
study aimed to evaluate the seroprevalence of anti-HEV 
IgG among kidney transplant recipients in Urmia, Iran.
3. Patients and Methods
The current descriptive, cross-sectional study was 
conducted with the approval of the Scientific and Ethi-
cal Review Board of Urmia University of Medical Sci-
ences (UMSU), in Urmia, Iran. 91 patients were selected 
randomly from amongst patients who had undergone 
kidney transplantation between 1991 and 2010 in the 
Department of Transplantation, Imam-Khomeini Train-
ing Hospital (almost 2000 cases), and referred to the 
Transplantation Clinic for follow-up. Informed consent 
was obtained from each patient prior to participation in 
the study. Two milliliter blood samples were obtained via 
venipuncture for serological analyses. Samples were cen-
trifuged and sera were separated immediately. Sera were 
stored at –20ºC, and tested for the presence of anti-HEV 
IgG antibody by enzyme-linked immunosorbent assay 
(ELISA, Dia.Pro; Diagnostic Bioprobes, Italy). The presence 
of anti-HEV IgG antibody was considered as the evidence 
for prior exposure to HEV (6).
All patients had been tested previously for HBsAg 
(Diasorin, USA), anti-HCV (Diasorin, USA), and anti-HIV 
(Biotest, Germany) using ELISAs. Blood samples were 
evaluated for alanine aminotransferase (ALT) levels us-
ing a Hitachi autoanalyzer 704 (Roche, Switzerland) with 
Pars Azmoon reagents kit (Tehran, Iran). Alanine amin-
otransferase levels greater than 1.5 times the upper nor-
mal limit were considered as elevated ALT levels. Data 
were collected regarding the following variables: age, 
sex, educational status, marital status, etiology of end-
stage renal disease (ESRD), duration of ESRD, history of 
hemodialysis (HD), history of blood transfusion and im-
munosuppressive therapy.
All collected data were analyzed using SPSS software 
Ver. 16 (Chicago, IL). Descriptive statistics were reported 
as the mean ± SD for continuous variables and as the fre-
quency (%) for dichotomous variables. To evaluate the re-
lationship between different factors, we performed chi-
square analysis. Quantitative variables were compared 
using independent t-test. P < 0.05 were considered sta-
tistically significant.
4. Results
Ninety-one renal transplant recipients were selected 
randomly from recipients who had undergone kidney 
transplantation between 1991 and 2010 in the Imam 
Khomeini Hospital in Urmia and they were enrolled in 
the study after giving informed consent for blood sam-
pling and laboratory assays. The mean age of the pa-
tients was 35.4 ± 14.5 years old (6–65 years old). 61 patients 
(67%) were men and the remaining (33%) were women. 59 
(64.8%) were married and 32 patients (35.2%) were single. 
19 patients (20.9%) were illiterate, 20 (22%) had studied 
until the elementary level, 10 (11%) attained guidance 
school level, 10 (11%) attained high school level, 31 (34%) 
had diplomas, and one (1.1%) patient had an academic 
degree.
The cause of renal failure among the patients was 
glomerulonephritis in 30 cases (33%),; hypertension in 
28 cases (30.8%),; polycystic kidney disease (PCKD) in 12 
cases (13.2%); renal atrophy in 3 cases; nephrolithiasis 
and focal-segmental glomerulosclerosis (FSGS) in 2 cas-
es; and DM, Alport syndrome, neurogenic bladder, and 
urinary infection each in one (1.1%) of the participants. 65 
patients (71.4%) had undergone HD prior to renal trans-
plantation, but 26 (28.6%) had no history of HD prior to 
transplantation. Only 37 subjects (40.7%) had a history 
of blood transfusion. Mean anti-HEV IgG titer was 1.47 ± 
2.16 (range, 0.14–7.31). 28 subjects (30.8%) were seroposi-
tive for anti-HEV IgG; however, 59 cases (64.8%) were sero-
negative, and 4 subjects (4.4%) had a borderline IgG titer 
(range, 0.9–1.1). We categorized patients with borderline 
anti-HEV titer as seronegative; accordingly, seronegative 
cases were increased to 63 cases (69.2%). None of the par-
ticipants, either in the anti-HEV positive group or in the 
seronegative group, were seropositive for blood-borne 
viruses (hepatitis B virus [HBV], hepatitis C virus [HCV], Hepat Mon. 2011;11(8):646-651
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or human immunodeficiency virus [HIV]). There was no 
statistically significant association between HEV sero-
positivity and the other viruses mentioned above.
A comparison of patient characteristics between the 
groups seropositive and seronegative for anti-HEV IgG 
is shown in Table 1. Seropositive patients were gener-
ally older than seronegative patients (P = 0.009). In this 
study, we did not find a significant correlation between 
HEV infection and level of education (P = 0.206) (Table 
1). There was no correlation between a history of blood 
transfusion and HEV infection (P = 0.164). Furthermore, 
chi-square analysis revealed no correlation between a 
history of pre-transplantation hemodialysis and HEV 
infection (P = 0.228). The mean ALT level was 68.5 ± 35.4 
units per liter (IU/L), when all patients were included in 
the calculation of the mean (27–262). The mean aspartate 
aminotransferase (AST) level was 51.4 ± 18.4 IU/L. The mean 
ALT level was 1.71 times the normal values. Fifty patients 
(54.9%) had normal ALT levels, but 41 patients (45.1%) had 
elevated ALT levels.
Chi-square analysis revealed no relationship between 
treatment with azathioprine and increase in liver en-
zymes (ALT) (Table 2). Further, there was no significant 
difference in the serum ALT level between anti-HEV sero-
positive and seronegative patients. Multinomial logistic 
regression indicated no significant relationship between 
HEV infections and increases in ALT levels, even after con-
trolling for treatment with azathioprine (P = 0.79, OR = 
1.12; 95% CI: 0.45–2.76).
5. Discussion
Renal transplant recipients are known to be suscep-
tible to viral infections, with more severe clinical pre-
sentations compared to healthy persons (13, 22). The 
increased susceptibility is due to immunosuppression, 
which is caused by treatment with immunosuppressive 
drugs. Recently, hepatitis E has become more important 
in organ transplant recipients. To date, hepatitis E had 
been believed to be a self-limited acute infection, which 
rarely becomes chronic. However, in recent years, some 
articles have reported HEV-related chronic hepatitis, and 
even cirrhosis, in organ transplant recipients (5, 17, 18, 
23, 24). Since persistent HEV viremia was also observed 
in patients with T-cell lymphoma while receiving chemo-
therapy (25), the cause of this chronicity could be immu-
nosuppression, which is similar in both patient groups.
Other studies have questioned the generalizability 
of these findings (chronicity of HEV infection in organ 
transplant recipients), since all the studies that de-
Characteristic Anti-HEV Positive (n = 28) Anti-HEV Negative (n = 63) P value
Age, y, mean ± SD 41.3 ± 12.4 32.8 ± 14.6 0.009
Sex, No. (%) 0.366
Male
Female
20 (71.4%)
8 (28.6%)
41 (65.1%)
22 (34.9%)
Education, No. (%) 0.206
Illiterate
Lower than diploma
Diploma and higher
9 (32.1%)
11 (39.3%)
8 (28.6%)
10 (15.9%)
29 (46%)
24 (38.1%)
History of blood transfusion, No. (%) 0.164
Positive
Negative
14 (50%)
14 (50%)
23 (36.5%)
40 (63.5%)
History of HD, No. (%) 0.228
Positive
Negative
22 (78.6%)
6 (21.4%)
43 (68.3%)
20 (31.4%)
ALT levels, No. (%) 0.48
Normal
Elevated
16 (57.1%)
12 (42.9%)
34 (54%)
29 (46%)
ALT, IU/L, mean ± SD 65.1 ± 40.7 70.0 ± 33.1 0.550
AST, IU/L, mean ± SD 47.9 ± 10.1 53.0 ± 21.0 0.229
Table 1. Patient Characteristics of Two Different Groups, Positive, or Negative, for the Anti-HEV IGg Antibody
Characteristic Treatment with Azathioprine, 
No. (%) (n = 30)
Not Treated with Azathioprine, 
No. (%)  (n = 61)
P value
Normal ALT level 18 (60%) 32 (52.5%) 0.325
Elevated ALT level 12 (40%) 29 (47.5%)
Table 2. Alanine Aminotransferase Levels among Patient Groups with or without Azathioprine in Their Immunosuppressive RegimenHepat Mon. 2011;11(8):646-651
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scribed chronic infection or cirrhosis in renal transplant 
patients reported infections with genotype 3 HEV, when 
viral genotyping was performed. However, genotype 3 is 
responsible for only a minor proportion of acute hepati-
tis E cases around the world (6, 13), and has different clin-
ical features compared to genotype 1 HEV. It seems to be a 
zoonotic infection in humans, whilst genotype 1, which is 
the most prevalent genotype of HEV in the world, is most-
ly transmitted via the fecal-oral route. Iran, located in the 
Middle East, is a country with few suspected outbreaks 
of HEV (7). A population-based study in Iran reported the 
prevalence rate of anti-HEV IgG among the healthy popu-
lation to be 9.6% (12). The prevalence rate among hemo-
dialysis patients was reported to be 7.4% in Tabriz, Iran 
(4). Therefore, the prevalence rate was lower than that in 
the general population. The differences were attributed 
to differences between the populations, the sample size, 
or the situation of public health services (4).
Hoseini-Moghaddam et al. stated that the seropreva-
lence of HEV in patient groups, such as HD patients, 
seems to be dependent on the prevalence of HEV infec-
tion in the general population (2). Kamar et al. reported 
the seroprevalence of HEV in French renal transplant re-
cipients to be 14.5% (5), whilst its prevalence in blood do-
nors in southwestern France, represented as the general 
population, was 16.6% (26). Our study revealed the sero-
prevalence of anti-HEV IgG to be significantly higher in 
transplant recipients than in the Iranian general popula-
tion, or in HD patients. Therefore, we conclude that the 
prevalence rate of anti-HEV IgG in transplant recipients 
is independent of its prevalence in the general popula-
tion. The seroprevalence of anti-HEV IgG among Iranian 
transplant recipients reported here is the highest report-
ed in the world in similar populations (2.7%–15.6%) (1, 5, 
20, 21). The high seroprevalence is even more interesting, 
considering the lower prevalence rate of HEV in the Ira-
nian general population than in most countries in which 
HEV is endemic.
It is possible that this high seroprevalence of HEV is 
due to infection with another unknown virus, which cre-
ates antibodies cross-reacting with HEV (27). The study of 
Kamar et al. determined the clinical importance of acute 
hepatitis E infection in organ transplant recipients, de-
spite all previous beliefs that considered Hepatitis E 
infection as a self-limited disease. Among 14 transplant 
recipients with acute hepatitis E infection, confirmed 
by elevated liver enzymes and positive HEV RNA tests, 8 
patients (57%) developed chronic hepatitis. The patient’s 
age was the only factor that was indicated to have a cor-
relation with HEV infection. Seropositive patients were 
generally older than seronegative patients (P = 0.009).
Moreover, the relatively rapid evolution to cirrhosis 
has been mentioned by some authors, particularly in the 
setting of kidney transplantation (18, 19). Further, Kamar 
et al. suggested that HEV infection in kidney transplant 
recipients is more severe that HCV infection (17, 28). Some 
studies have proposed blood transfusion as a potential 
route of HEV transmission, particularly in areas of high 
endemicity (14, 15, 29). However, in this study, we did not 
find any correlation between a history of blood transfu-
sion and HEV infection. Certain drugs are also considered 
a probable cause of an increase in liver enzymes, when 
other frequent causes have been ruled out. Hepatotoxic 
features have been reported in 2 immunosuppressive 
drugs, azathioprine (30) and sirolimus (31).
In our study, chi-square analysis revealed no relation-
ship between treatment with azathioprine and increase 
in liver enzymes (ALT). Further, there was no significant 
difference in the serum ALT levels of anti-HEV seroposi-
tive and seronegative patients. Multinomial logistic re-
gression indicated no significant relationship between 
HEV infection and increase in ALT levels, even after con-
trolling for treatment with azathioprine. In this study, 12 
(42.9%) cases of 28 seropositive recipients had high ALT 
levels. This is in accordance with previous findings by 
Kamar et al. in France (14 of 46 seropositive cases: 35%) 
(5). The overall prevalence of individuals with abnormal 
ALT in general population is demonstrated to be 11%–13%. 
In 25%–35% of individuals with abnormal ALT, the prob-
able cause is nonalcoholic fatty liver disease (32, 33). In 
this study, the prevalence rate of abnormal ALT level in 
the HEV seronegative patients was 46%, which is con-
siderably higher than the rates reported in the general 
population. However, in our study the cases and controls 
were both transplant recipients, who have their own risk 
factors (i.e., the immunosuppressive treatment) for liver 
function impairment.
We did not find a significant correlation between HEV 
infection and the level of education. This was in accor-
dance with the study of Mathur et al. (34), where the prev-
alence of HEV was found to be lower in rural areas, with 
high number of uneducated people than in urban areas, 
but in contrast to the study of HEV risk factors among 
pregnant women in Turkey (35). However, since the de-
sign of our study was not suitable for comparing the anti-
HEV antibody among different patient groups (different 
sexes, educational status, history of blood transfusion 
etc.), we cannot rely on P-values completely, and the re-
sults should be interpreted cautiously. In our study, none 
of the participants were seropositive for blood-borne vi-
ruses (HBV, HCV, and HIV). Consequently, there was no 
statistically significant association between HEV sero-
positivity and the other viruses mentioned above. This 
was in accordance with the findings of another study 
from Iran among HD patients (4), but in contrast to the 
findings of Pisanti et al. from Italy, which reported an as-
sociation between hepatitis C and HEV infection (36).
We did not evaluate all the samples or even the sero-
positive cases for serum anti-HEV IgM or HEV RNA. There-
fore, we cannot draw any conclusions regarding the 
timing of exposure, prior or recent, of our seropositive 
patients to HEV. Since we did not investigate the subjects 
for anti-HEV IgM or HEV RNA, any conclusions regarding 
the correlation between anti-HEV IgG and elevated ALT 
levels cannot be further confirmed. Further, from our 
data, we cannot discuss the acuteness or chronicity of Hepat Mon. 2011;11(8):646-651
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HEV infection; first, because of the lack of information 
regarding anti-HEV IgM or HEV RNA, and second, due to 
the cross-sectional design of the study. As mentioned be-
fore, the most common route of transmission for HEV is 
the fecal-oral route (2, 6). In this study we did not identify 
any source for HEV contamination. Nonetheless, consid-
ering the fecal-oral route as the main route of transmis-
sion in endemic regions, we anticipate that the virus was 
transmitted via water and food intake.
Several HEV vaccines have been produced to date, but 
they have not reached the market yet (6). Furthermore, 
cost-effectiveness analysis is needed to provide proper 
advice regarding the appropriateness of anti-HEV vacci-
nation in transplant recipients prior to transplantation. 
Several studies have demonstrated that chronic viral 
hepatitis E could be a silent disease in graft recipients (5). 
The authors of these studies suggested that clinicians 
should not look merely for clinical evidence to consider 
hepatitis E. Chronic patients may have normal liver en-
zymes or remain seronegative (2); therefore, long-term 
follow-up of the patients is recommended. The anti-HEV 
IgG antibody has a high prevalence in Iranian kidney 
transplant recipients, and it is significantly higher in 
comparison with that in previous studies in the general 
population or HD patients.
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